SCHEMBL4850370

SCHEMBL4850370

CC(C)C1CNCC(C(C)C)C1

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.32
GBA1 P04062 3/20 0.31
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA7 P36544 1/20 0.30
CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438915 0.87
SCHEMBL25673706 0.84
SCHEMBL19294779 0.84
SCHEMBL22327695 0.84
SCHEMBL19316948 0.84
SCHEMBL24251319 0.84
SCHEMBL24558824 0.84 GBA1 (0.31) GBA1
SCHEMBL24843777 0.84 GBA1 (0.31) GBA1
SCHEMBL24584509 0.84 GBA1 (0.31) GBA1
SCHEMBL19294778 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092138-A1 BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT KOEI CHEMICAL COMPANY, LIMITED (JP) 2026-04-02 US disclosed
US-20230382865-A1 HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-30 US disclosed
US-20230346942-A1 MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-11-02 US disclosed
US-20230346942-A1 MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-11-02 US disclosed
US-11802132-B2 Small molecules for inducing selective protein degradation and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-31 US disclosed
US-11730810-B2 Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-08-22 US disclosed
US-11725011-B2 Bicyclic urea kinase inhibitors and uses thereof THE GENERAL HOSPITAL CORPORATION (US) 2023-08-15 US disclosed
US-11725011-B2 Bicyclic urea kinase inhibitors and uses thereof THE GENERAL HOSPITAL CORPORATION (US) 2023-08-15 US disclosed
US-20230234959-A1 BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-07-27 US disclosed
US-20230233549-A1 METHODS OF USING 4(1H)-QUINOLONE DERIVATIVES ACADEMIA SINICA (TW) 2023-07-27 US disclosed
US-20110178058-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES, INC. (US) 2011-07-21 US disclosed
US-20110178129-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES, INC. (US) 2011-07-21 US disclosed
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases PFIZER, INC. 2011-02-24 US disclosed
US-20110020278-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES, INC. (US) 2011-01-27 US disclosed
US-20100160290-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE SHIONOGI & CO., LTD. (JP) 2010-06-24 US disclosed
US-20090082560-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2009-03-26 US disclosed
US-7371746-B2 1,2,4-Thiadiazole compounds and pests controlling composition containing the same SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2008-05-13 US disclosed
EP-1765798-A2 1,2,4- THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2007-03-28 EP disclosed
US-20070004722-A1 1,2,4-Thiadazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-01-04 US disclosed
WO-2005037805-A2 1,2,4-THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382865-A1 HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF KDM5A, KDM5B, KDM5C CCR5 4641/4885GBA1 3742/4885CHRNB2 4082/4885
US-20100160290-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE NR1H2, NR1H3, NR0B1 CCR5 830/4885GBA1 610/4885CHRNB2 42/4885
US-20260092138-A1 BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT RER1, RPP30, REV1 CCR5 1636/4885GBA1 2381/4885CHRNB2 1505/4885
US-20110178058-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, CYP2F1, CYP4F3 CCR5 1224/4885GBA1 220/4885CHRNB2 4880/4885
US-11730810-B2 Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response CD4, MYD88, STING1 CCR5 183/4885GBA1 1347/4885CHRNB2 4087/4885
US-20070004722-A1 1,2,4-Thiadazole compounds and use thereof CYP4F3, CYP4B1, CYP4X1 CCR5 845/4885GBA1 2035/4885CHRNB2 3538/4885
US-11802132-B2 Small molecules for inducing selective protein degradation and uses thereof BAZ2A, BRD3, BRPF3 CCR5 3927/4885GBA1 3783/4885CHRNB2 3253/4885
US-20090082560-A1 AMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP CCR5 2369/4885GBA1 451/4885CHRNB2 258/4885
US-20110020278-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, CYP2F1, CYP4F3 CCR5 1224/4885GBA1 220/4885CHRNB2 4880/4885
US-20230234959-A1 BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF SIK1, SIK2, SIK3 CCR5 3856/4885GBA1 1269/4885CHRNB2 4420/4885
US-11725011-B2 Bicyclic urea kinase inhibitors and uses thereof SIK1, SIK2, SIK3 CCR5 3856/4885GBA1 1269/4885CHRNB2 4420/4885
US-20110178129-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, CYP2F1, CYP4F3 CCR5 1224/4885GBA1 220/4885CHRNB2 4880/4885
US-20230233549-A1 METHODS OF USING 4(1H)-QUINOLONE DERIVATIVES TUBB1, TUBB3, TUBB CCR5 2433/4885GBA1 1372/4885CHRNB2 2528/4885
US-20230346942-A1 MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF CRY1, MAPT, PYGL CCR5 1083/4885GBA1 174/4885CHRNB2 3832/4885
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases SNCA, PARK7, HTT CCR5 3117/4885GBA1 29/4885CHRNB2 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.